MedTrace Logo

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD

NCT01201187 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2019-02-25

No results posted yet for this study

Summary

This study will evaluate clinical efficacy and safety of treatment with YY-162 in children with ADHD

Conditions

  • Mental Disorders

Interventions

DRUG

YY-162

YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication

DRUG

Placebo

Placebo 1T/twice a day(bid) for 8weeks, po medication

Sponsors & Collaborators

  • Yuyu Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Soo-Churl Cho, MD, Ph.D · Seoul National University Hospital

  • Hyun Ju Hong, MD,Ph.D · Hallym University Hospital

  • EunJin Park, MD · Inje University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-04-30
Completion
2011-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01201187 on ClinicalTrials.gov